Sale

Anti-Infectives Market

Global Anti-Infectives Market Trends, Size, Forecast: By Drug Type: Antibiotics, Antifungal, Antiviral, Others; By Indication: HIV Infection, Pneumonia, Respiratory Virus Infection, Sepsis, Tuberculosis, Others indication; By Route of Administration: Topical, Oral, Others; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Anti-Infectives Market Outlook

The global anti-infectives market size was valued at USD 128.71 billion in 2023, driven by the rising prevalence of infectious diseases caused due to unhealthy environments, lack of proper sanitation, and unhygienic lifestyle. The market is anticipated to grow at a CAGR of 4.3% during the forecast period 2024-2032 to reach a value of USD 188.00 billion by 2032.

 

Increasing Incidences of Infectious Diseases Boosting the Market Growth of Anti-Infectives

The rising prevalence of infectious diseases, particularly across the low- and middle-income countries, has led to a surge in demand for anti-infectives to curtail the spread of infection. This has been driving the market growth of anti-infectives.

 

Global Anti-Infectives Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

As a result of the increasing incidences of infectious agents, including bacteria, fungi, and viruses that are born from unhealthy environments lacking proper sanitation has led to the increasing incidences of diseases like diarrhoea, seasonal viral fevers, and skin infections, among others. Anti-infective agents act against the reproduction of the source of infection in the body over the course of time, and hence gradually killing the infection. Thus, the effectiveness of anti-infective agents is propelling the growth of the market.

 

Anti-Infectives: Market Segmentation

Anti-infectives are medicines that are capable of restraining the spread of an infectious disease inside the body. These medicines can either be injected, consumed orally, or can be applied to the skin as ointments or creams.

 

Global Anti-Infectives Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

On the basis of type, the market can be divided into:

  • Antibacterial
  • Antifungal
  • Antiviral

Based on route of administration, the market can be categorised into:

  • Topical
  • Oral
  • Intravenous (IV) 
  • Others

The market, based on distribution channel, can be segmented into:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Speciality Pharmacy
  • Online
  • Others

The EMR report looks into the regional markets of anti-infectives like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

 

Robust Investments into Research and Development (R&D) Invigorating the Market Growth of Anti-Infectives

The market for anti-infectives is rapidly growing due to the robust investments aimed at research and development (R&D) for the production of effective anti-infectives. Owing to the increasing antimicrobial resistance to existing anti-infective agents, the pharmaceutical sector is constantly innovating and researching to produce strong anti-infectives, which is augmenting the growth of the market. In addition, robust commercialisation schemes aimed at spreading knowledge about the existence of anti-infective agents in the market is furthering the market growth of anti-infectives. Moreover, the increasing awareness regarding the avoidable risks associated with early treatment of infectious diseases is further boosting the market growth of anti-infectives globally.

 

Global Anti-Infectives Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Industry Players in the Global Anti-Infectives Market

The report presents a detailed analysis of the following key players in the global anti-infectives market, looking into their capacity, market share, and latest developments like capacity expansions, plant turnabouts and mergers and acquisitions:

  • Gilead Sciences, Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Abbott Laboratories
  • Others

The comprehensive report looks at the micro and macro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of the Porter’s Five Forces Model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Type
  • Indication
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Drug Type
  • Antibiotics
  • Antifungal
  • Antiviral
  • Others
Breakup by Indication
  • HIV Infection
  • Pneumonia
  • Respiratory Virus Infection
  • Sepsis
  • Tuberculosis
  • Others indication
Breakup by Route of Administration
  • Topical
  • Oral
  • Intravenous (IV)
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Gilead Sciences, Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Abbott
  • Alcon Pharmaceuticals Ltd.
  • Astellas Pharma Inc.
  • Astrazeneca plc.
  • Bayer Healthcare AG
  • Alkem Labs
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Infectious Disease Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Infectious Disease Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Infectious Disease Epidemiology (2016-2031)
    5.3    Europe Infectious Disease Epidemiology (2016-2031)
    5.4    Asia-Pacific Infectious Disease Epidemiology (2016-2031)
    5.5    Latin America Infectious Disease Epidemiology (2016-2031)
    5.6    Middle East & Africa Infectious Disease Epidemiology (2016-2031)
6    Global Anti-Infective Market Overview 
    6.1    Global Anti-Infective Market Historical Value (2017-2023) 
    6.2    Global Anti-Infective Market Forecast Value (2024-2032)
7    Global Anti-Infective Market Landscape
    7.1    Anti-Infective: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Anti-Infective: Product Landscape
        7.2.1    Analysis by Drug Type
        7.2.2    Analysis by Indication
        7.2.3    Analysis by Route of Administration
        7.2.4    Analysis by Distribution Channel
8    Anti-Infective Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Anti-Infective Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Anti-Infective Market Segmentation
    11.1    Global Anti-Infective Market by Drug Type
        11.1.1    Market Overview
        11.1.2    Antibiotics
        11.1.3    Antifungal
        11.1.4    Antiviral
        11.1.5    Others
    11.2    Global Anti-Infective Market by Indication
        11.2.1    Market Overview
        11.2.2    HIV Infection
        11.2.3    Pneumonia
        11.2.4    Respiratory Virus Infection
        11.2.5    Sepsis
        11.2.6    Tuberculosis
        11.2.7    Others indication
    11.3    Global Anti-Infective Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Topical
        11.3.3    Oral
        11.3.4    Intravenous (IV)
        11.3.5    Others
    11.4    Global Anti-Infective Market by Distribution Channel
        11.4.1    Market Overview
        11.4.2    Hospital Pharmacy
        11.4.3    Retail Pharmacy
        11.4.4    Online Pharmacy
        11.4.5    Others
    11.5    Global Anti-Infective Market by Region
        11.5.1    Market Overview
        11.5.2    North America
        11.5.3    Europe 
        11.5.4    Asia Pacific
        11.5.5    Latin America
        11.5.6    Middle East and Africa
12    North America Anti-Infective Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Anti-Infective Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Anti-Infective Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Anti-Infective Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Anti-Infective Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Gilead Sciences, Inc.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Sandoz International GmbH
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Pfizer Inc.
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    GlaxoSmithKline plc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Abbott
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Alcon Pharmaceuticals Ltd.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Astellas Pharma Inc.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Astrazeneca plc.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Bayer Healthcare AG
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Alkem Labs
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
24    Anti-Infective - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global anti-infectives market reached a value of USD 128.71 billion in 2023.

The market is anticipated to grow at a CAGR of 4.3% during the forecast period of 2024-2032 to reach a value of USD 188.00 billion by 2032.

The market is being driven by the rising prevalence of infectious diseases caused due to unhealthy environments, lack of proper sanitation, and unhygienic lifestyles.

Robust investments into the pharmaceutical sector for the development of advanced anti-infectives  and growing awareness regarding the early treatment of infection is leading to the growth of the market.

The major regional markets for anti-infectives are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

The major types of anti-infectives are antibacterial, antifungal, and antiviral.

The different routes of administration are topical, oral, and intravenous (IV), among others.

The various distribution channels of anti-infectives are hospital pharmacy, retail pharmacy, speciality pharmacy, and online, among others.

The major players in the industry are Gilead Sciences, Inc., Sandoz International GmbH, Pfizer Inc., GlaxoSmithKline plc., and Abbott Laboratories, among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER